Neuromodulation for Better Health
Parasym (parasym.co) scores 83 out of 100 on Brand Analyzer, placing it in the Strong Brand tier among Healthcare brands, Technology brands, in the 88th percentile of 19006 Healthcare brands.
Parasym is a British neurotechnology company founded in 2017 and headquartered in London. It develops a new class of bioelectronic medicine that delivers targeted bioelectrical signals to neural circuits of organs, aiming to treat chronic diseases without surgery or drugs. The company positions itself as a scientific pioneer in neuromodulation, working to translate communication between the brain and body into non-invasive therapies. Its stated mission is to advance quality of life for one billion people through breakthrough neuromodulation science, targeting patients, healthcare providers, and researchers interested in innovative bioelectronic treatments.
| Brand Name | Parasym |
|---|---|
| Domain | parasym.co |
| Industry | Healthcare, Technology |
| Founded | 2017 |
| Headquarters | London |
| Main Competitors | SetPoint Medical, Galvani Bioelectronics, electroCore (85/100), Cala Health (82/100), Nevro (76/100), Neuros Medical, Spark Biomedical |
Moz Domain Authority 34/100 vs category average 40 / leader 97 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Parasym is pioneering a new class of treatment that uses bioelectrical signals targeted to neural circuits of organs, treating disease without surgery or drugs." (Meta description: 24 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, og:title, og:description, og:image, og:type, Twitter cards. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, Webflow.
Social footprint: verified profiles on X (Twitter), LinkedIn, Facebook, Instagram, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Parasym?", Claude could identify the brand as of October 2026. Parasym is a health technology company known for its tVNS (transcutaneous vagus nerve stimulation) device, a non-invasive wearable used mainly in research settings to stimulate the vagus nerve via the ear. Best known for Non-invasive transcutaneous vagus nerve stimulation (tVNS) devices used in clinical and academic research.
When asked "Best brands similar to Parasym?", Claude would recommend Parasym as of October 2026. It's a recognized name in the niche vagus nerve stimulation research space, so it would come up if someone asked about tVNS technology providers.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Parasym's main competitors in Healthcare: electroCore (85/100), Cala Health (82/100), Nevro (76/100).
Sources: Brand Analyzer scan
Parasym has limited AI-search visibility, scoring 34/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 36, recommendation 54). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Parasym official site
Parasym was founded in 2017. Parasym operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Parasym is headquartered in London. Parasym operates in the Healthcare category.
Sources: Wikidata
Parasym scores 54/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Parasym official site
Parasym is a British neurotechnology company founded in 2017 and based in London. It specializes in bioelectronic medicine, developing treatments that use targeted bioelectrical signals to neural circuits of organs as an alternative to surgery or drug-based therapies.
Sources: Parasym official site
Parasym develops a new class of medical treatment that applies targeted bioelectrical signals to the neural circuits of organs. This approach is designed to treat chronic diseases without the need for surgery or pharmaceutical drugs, using neuromodulation science to influence communication between the brain and body.
Sources: Parasym official site
Parasym can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Parasym official site
Parasym offers bioelectronic medicine treatments that use targeted bioelectrical signals directed at the neural circuits of organs. These treatments are designed to address chronic diseases without requiring surgery or pharmaceutical drugs, reflecting the company's focus on neuromodulation-based therapeutic solutions.
Sources: Parasym official site
Parasym is known for pioneering non-invasive, drug-free bioelectronic medicine that targets neural circuits of organs using bioelectrical signals. It is recognized as a scientific innovator in the neuromodulation field, positioning itself at the intersection of neuroscience and technology to treat chronic disease.
Sources: Parasym official site
Parasym's technology is intended for patients seeking non-invasive treatment options for chronic diseases, as well as healthcare providers and researchers interested in bioelectronic medicine and neuromodulation science.
Sources: Parasym official site
Parasym scores 34/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Parasym has a weak AI-visibility profile at 34/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (54/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, open access for AI crawlers (GPTBot, ClaudeBot, etc.) and machine-readable schema.org markup. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 34/100 and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Parasym from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Parasym: ParaMed (83/100), PAI (83/100), Parata (83/100), Parkinson's UK (83/100).
A step up - brands to learn from: Zoetis (91/100), theSkimm (91/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.